SSCIP Accelerates Industrial Projects Again and Welcomes the Entry of Four more Projects

On July 16, an open tender was carried out for 6 land plots in Singapore-Sichuan Hi-Tech Innovation Park (SSCIP). They were acquired by CDHTI Assets Management Co., Ltd.（wholly-owned subsidiary of CDHT Investment Group）, Chengdu Jiarui Nengda Industry Co., Ltd. (wholly-owned subsidiary of Good Doctor Pharmaceutical Group) and Chengdu Chipscreen Pharmaceutical Co., Ltd. (wholly-owned subsidiary of Chipscreen Biosciences) respectively, and Sichuan Tianyuan Real Estate Co., Ltd.

CDHTI Assets Management Co., Ltd. (CDHTI Assets Management): Building a Biomedical Innovation Park in SSCIP

CDHTI Assets Management is a subsidiary of CDHT Investment Group. The group is a wholly-owned corporation subordinated to CDHT Management Committee and responsible for the overall development of South Park and West Park of CDHT. The Biomedical Innovation Park will be established in Cluster 4 of SSCIP, with a total planned investment of RMB 1,680 million and a total floor area of 286,000 m2. For those small and medium enterprises without land acquisition demand, the Park is a preferential platform to settle in. It is estimated that the enterprises would enjoy the same policies as of Tianfu Software Park and Tianfu Life Science Park.

Location of Plot No.1: Group 5 and 11, Longdengshan Community, Zhonghe Subdistrict

• Site area (m2): 111904.15

• Site area (mu): 167.8562

• Land use: Other commercial services/commercial

• Pilot ratio: 111,904.15m2≤GFA≤223,808.3m2, incl. commercial building area ≤67,142.49m2 (please refer to the overall selling scheme for the details)

• Bid winner: CDHTI Assets Management Co., Ltd.

Good Doctor Pharmaceutical Group: Relocating its Headquarters and R&D Center to SSCIP
Sichuan Good Doctor Pharmaceutical Group’s main strategy is to launch the Big Health industry as its core focus. Now it has 28 wholly-owned subsidiaries, 8 GMP production factories, and 2 GAP medical groups with modern cultivation bases. Its massive sales network covers Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, even Europe and US. When Sichuan Good Doctor Pharmaceutical Group relocates its headquarters and R&D center to SSCIP, it will become a new medical epicenter of West China, and firmly establish a high-end medical industrial chain with world-class standard in SSCIP.

Location of Plot No.2: Group 12, Longdengshan Community, Zhonghe Subdistrict

• Site area (m2): 19999.95

• Site area (mu): 29.9999

• Land use: Other commercial services/commercial

• Pilot ratio: 19,999.95m2≤GFA≤39,999.9m2, incl. commercial building area ≤15,999.96m2 (please refer to the overall selling scheme for the details)

• Bid winner: Chengdu Jiarui Nengda Industry Co., Ltd.

Chipscreen Biosciences: Setting Up its Novel Pharmaceutical R&D Center and Regional Headquarters in SSCIP
Chipscreen Biosciences is a leading biomedical company specialized in the discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of production lines covering from lab to preclinical/clinical research and mass production in three areas of tumor, diabetes/metabolic diseases, nerve/immunology. Chipscreen plans to set up its novel pharmaceuticals R&D center and regional headquarters in SSCIP, with a total investment of around RMB 400 million.

Location of Plot No.3: Group 12, Longdengshan Community, Zhonghe Subdistrict

• Site area (m2): 16697.40

• Site area (mu): 25.0461

• Land use: Other commercial services/commercial

• Pilot ratio: 16,697.4m2≤GFA≤33,394.8m2 (please refer to the overall selling scheme for the details)

• Bid winner: Chengdu Chipscreen Pharmaceutical Co., Ltd.

Location of Plot No.4: Group 4 and 5, Jinsong Community, Zhonghe Subdistrict

• Site area (m2): 19917.03

• Site area (mu): 29.8755

• Land use: Other commercial services

• Pilot ratio: 17,179.85m2≤GFA≤51,539.55m2 (please refer to the overall selling scheme for the details)

• Bid winner: Sichuan Tianyuan Real Estate Co., Ltd.

SSCIP Accelerates the Entry of Industrial Projects
So far, SSCIP have signed investment agreements with a dozen of enterprises, 5 of which have successfully settled in the Park and are planning to start construction in the second half of this year. It can be predicted that more industry leading enterprises will flock to the Park in succession while SSCIP devotes more effort in the global investment attraction.

Note: For more information, please refer to the Notice on Land Transaction released by the Bureau of Land and Resources Chengdu http://www.cdggzy.com:8112/three/pmjg_xx.aspx?RID=5001